Mark Eisner - 24 Feb 2026 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Reporting relationship: EVP and Chief Medical Officer
Issuer ticker: VIR
Reported as of: 24 Feb 2026
Net transaction value: -$33,955
SEC form: 4
Accepted by SEC: 26 Feb 2026, 16:55:19 UTC
Prior SEC filing: 24 Feb 2026
Next SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Vanina de Verneuil, Attorney-In-Fact

Key filing fact

Mark Eisner filed Form 4 for Vir Biotechnology, Inc. (VIR) on 26 Feb 2026.

Key facts

This page summarizes Mark Eisner's Form 4 filing for Vir Biotechnology, Inc. (VIR).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 26 Feb 2026, 16:55.

Change

Previous filing in this sequence was filed on 24 Feb 2026.
Current net transaction value: -$33,955.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001834161 Primary reporting owner

Eisner Mark

Relationship: EVP and Chief Medical Officer
Address: C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO
Signature: /s/ Vanina de Verneuil, Attorney-In-Fact
Signature date: 26 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VIR transaction

Common Stock

Sale

Transaction value: $15,405
Shares: -1,616
Change %: -1%
Price: $9.53
Shares after: 155,913
Date: 24 Feb 2026
Ownership: Direct
Footnotes: F1

VIR transaction

Common Stock

Sale

Transaction value: $18,550
Shares: -1,889
Change %: -1.2%
Price: $9.82
Shares after: 154,024
Date: 25 Feb 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

Footnote F2

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.